Interim report January – September 2013

High growth and improved income
Third quarter:

Continuing operations

  · Sales growth was 33 percent in local currency. Sales amounted to SEK 109
(83) million, corresponding to an increase of 31 percent in SEK.
  · Operating income (EBIT) amounted to SEK 23 (15) million, corresponding to an
operating margin of 21 (18) percent.
  · The comparative figures for 2012 relate to continuing operations, fertility,
unless otherwise stated.
  · Net income amounted to SEK 17 (9) million, which gave earnings per share of
SEK 0.85 (0.45).
  · Agreement with Xvivo Perfusion AB to terminate contract manufacturing of
STEEN Solution™ during the fourth quarter of 2013.

January - September:

Continuing operations

  · Sales growth was 30 percent in local currency. Sales amounted to SEK 329
(264) million, corresponding to an increase of 25 percent in SEK.
  · Operating income (EBIT) amounted to SEK 59 (38) million, corresponding to an
operating margin of 18 (14) percent.
  · The comparative figures for 2012 relate to continuing operations, fertility,
unless otherwise stated.
  · Net income amounted to SEK 41 (27) million, which gave earnings per share of
SEK 2.06 (1.36).

Gothenburg, November 7, 2013

VITROLIFE AB (publ)

Thomas Axelsson, CEO
Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
November 7, 2013 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical
device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/)
product area develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 230
employees and the company's products are sold in almost 110 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/
Interim report January – September 2013

Attachments
